Capecitabine and Thalidomide in Previously Treated Metastatic Colorectal Carcinoma
Information source: Dana-Farber Cancer Institute
ClinicalTrials.gov processed this data on August 23, 2015 Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Colorectal Adenocarcinoma
Intervention: Capecitabine (Drug); Thalidomide (Drug)
Phase: Phase 2
Status: Completed
Sponsored by: Dana-Farber Cancer Institute Official(s) and/or principal investigator(s): Charles S. Fuchs, MD, MPH, Principal Investigator, Affiliation: Dana-Farber Cancer Institute
Summary
The purpose of this study is to collect information about the antitumor activity and the
safety of capecitabine and thalidomide in patients with colorectal cancer.
Clinical Details
Official title: A Phase II Trial of Capecitabine and Thalidomide in Previously Treated Metastatic Colorectal Carcinoma
Study design: Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Primary outcome: To assess the anti-tumor activity of capecitabine and thalidomide when administered to patients with previously treated metastatic colorectal cancer.
Secondary outcome: To evaluate the safety of capecitabine and thalidomide in this patient population.
Detailed description:
- Patients will take capecitabine orally twice a day for two weeks followed by a one week
break period. These three week cycles will continue as long as the patient continues
to benefit from the the therapy and does not experience intolerable side effects.
- Thalidomide will be taken orally once daily in the evening. Each week teh daily dose
of the medication will be increased by 100mg as long as the patient is not experiencing
any moderate to severe side effects. The dose will be increased in this manner until
the daily dose is 600mg. If side effects do develop, the dose will either be held
constant or decreased until the side effects resolve. If the side effects do not
resolve, treatment will be stopped.
- Before starting treatment and periodically throughout the study, a physical exam,
routine blood tests, scans and x-rays will be done to monitor the body's response to
the treatment.
- For women patients, pregnancy tests will be performed every 3 weeks while on therapy.
- Scans and x-rays will be performed every 9 weeks (after every 3 cycles of treatment) to
follow the effects of the study drugs on the tumor.
Eligibility
Minimum age: 18 Years.
Maximum age: N/A.
Gender(s): Both.
Criteria:
Inclusion Criteria:
- Histologic proof of colorectal adenocarcinoma with radiological or cytological
evidence of stage IV (metastatic) disease
- Measurable tumor
- Serum creatinine < 1. 5 mg/dl
- Total bilirubin < 2. 0 mg/dl
- AST < 5 x ULN
- ANC > 1,500/mm3
- Platelets > 100,000/mm3
- Hemoglobin > 9. 0 gm/dl
- Must have received at least one prior chemotherapy regimen for metastatic colorectal
cancer. At least 3 weeks must have passed since the last chemotherapy treatment
- 18 years of age or older
- ECOG performance status of less than or equal to 2
- Life expectancy of greater than 12 weeks
Exclusion Criteria:
- Prior treatment with mitomycin C or nitrosourea compounds
- Prior treatment with capecitabine or thalidomide
- Clinically apparent central nervous system metastases or carcinomatous meningitis
- Peripheral neuropathy of grade 2 or greater severity
- Myocardial infarction in the past 6 months
- Major surgery in the past 2 weeks
- Uncontrolled serious medical or psychiatric illness
- Pregnant or lactating women
- Concurrent malignancy of any site, except limited basal cell carcinoma or squamous
cell carcinoma of the skin or carcinoma in situ of the cervix.
- Known allergy to 5-FU
Locations and Contacts
Dana-Farber Cancer Institute, Boston, Massachusetts 02115, United States
Massachusetts General Hospital, Boston, Massachusetts 02114, United States
Additional Information
Starting date: November 2001
Last updated: December 20, 2007
|